MecA
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats MecA as ChEMBL target CHEMBL6187, mapped to UniProt Q7DHH4. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why MecA matters
MecA is reviewed as MecA (UniProt Q7DHH4); MecA shows approved-linked disease relevance led by bacteriemia. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 0 approved drugs, 110 compounds, and 39 assays, with lead potency reaching pChEMBL 6.9.
MecA Sequence length is 668 aa.
Review this target as MecA, mapped to UniProt Q7DHH4. Sequence length is 668 aa.
Protein source · UniProt accession via ChEMBL component mappingMecA shows approved-linked disease relevance led by bacteriemia. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include CEFTOBIPROLE MEDOCARIL SODIUM.
Start review with bacteriemia because it currently carries approved-linked support. Linked drugs include CEFTOBIPROLE MEDOCARIL SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 0 approved drugs, 110 compounds, and 39 assays for this target. The dominant activity type is IC50. CHEMBL4847813 is the current potency anchor at pChEMBL 6.9.
Use CHEMBL4847813 as the tractability anchor when discussing potency (pChEMBL 6.9).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why MecA matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt Q7DHH4, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need to see why bacteriemia is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4847813
|
6.9 | Kd | — |
|
|
No preferred name
CHEMBL4879273
|
6.8 | Kd | — |
|
|
No preferred name
CHEMBL4862632
|
6.6 | Kd | — |
|
|
No preferred name
CHEMBL520642
|
5.7 | IC50 | Clinical |
|
|
No preferred name
CHEMBL5274536
|
4.7 | Kd | — |